Research Site

Blacktown 2148

2 studies enrolling now · 8 studies all time

What they study most

Advanced Solid Tumors, Carcinoma, Diabetes Mellitus, Type 2, Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD), Endometrial Cancer, Heart Failure and Impaired Kidney Function, Metastatic Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer, Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

Studies at this site

• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations — Recruiting now
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function — Recruiting now
• DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer — Recruiting now
• A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors — Running, not enrolling
• A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors — Running, not enrolling
• Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old — Completed
• MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. — Completed
• Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia — Completed